MALT1 inhibitors are currently being investigated in a handful of early phase clinical trials (e.g., ClinicalTrials.gov identifier: NCT04876092, NCT04859777, NCT05144347) in solid and hematological cancers, however, their therapeutic potential in autoimmune inflammatory diseases remains untested. The gene discussed is MALT1; the disease is hematopoietic and lymphoid cell neoplasm.